Pieter Johan Adam Eichhorn
Overview
Explore the profile of Pieter Johan Adam Eichhorn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
415
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Li B, Yan J, Phyu T, Fan S, Chung T, Mustafa N, et al.
Blood
. 2019 Aug;
134(23):2046-2058.
PMID: 31434700
Oncogenic EZH2 is overexpressed and extensively involved in the pathophysiology of different cancers including extranodal natural killer/T-cell lymphoma (NKTL). However, the mechanisms regarding EZH2 upregulation is poorly understood, and it...
12.
Saei A, Eichhorn P
Cancers (Basel)
. 2019 Aug;
11(8).
PMID: 31416288
The introduction of v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors in melanoma patients with BRAF (V600E) mutations has demonstrated significant clinical benefits. However, rarely do tumours regress completely....
13.
Saei A, Eichhorn P
Mol Cell Oncol
. 2018 Sep;
5(5):e1497862.
PMID: 30263945
Response to targeted therapies is limited by the activation or inhibition of feedback loops. Here we report the ubiquitin specific peptidase 28/F-box WD repeat-containing protein 7 (USP28/FBW7) complex functions as...
14.
Charles Richard J, Eichhorn P
SLAS Technol
. 2018 Jun;
23(6):493-506.
PMID: 29945466
Prior to the sequencing of the human genome, it was presumed that most of the DNA coded for proteins. However, with the advent of next-generation sequencing, it has now been...
15.
Saei A, Palafox M, Benoukraf T, Kumari N, Jaynes P, Iyengar P, et al.
J Exp Med
. 2018 Jun;
215(7):1913-1928.
PMID: 29880484
RAF kinase inhibitors are clinically active in patients with BRAF (V600E) mutant melanoma. However, rarely do tumors regress completely, with the majority of responses being short-lived. This is partially mediated...
16.
Charles Richard J, Eichhorn P
Oncotarget
. 2018 May;
9(28):20179-20212.
PMID: 29732012
Breast cancer is the second leading cause of cancer related deaths in women. It is therefore important to understand the mechanisms underlying breast cancer development as well as raises the...
17.
Kumari N, Jaynes P, Saei A, Iyengar P, Charles Richard J, Eichhorn P
Biochim Biophys Acta Rev Cancer
. 2017 Sep;
1868(2):456-483.
PMID: 28923280
The initial experiments performed by Rose, Hershko, and Ciechanover describing the identification of a specific degradation signal in short-lived proteins paved the way to the discovery of the ubiquitin mediated...
18.
Lui S, Iyengar P, Jaynes P, Bin Adam Isa Z, Pang B, Tan T, et al.
EMBO Rep
. 2017 Apr;
18(5):797-808.
PMID: 28381482
The amplitude of transforming growth factor-β (TGF-β) signal is tightly regulated to ensure appropriate physiological responses. As part of negative feedback loop SMAD7, a direct transcriptional target of downstream TGF-β...
19.
Iyengar P, Jaynes P, Rodon L, Lama D, Law K, Lim Y, et al.
Sci Rep
. 2015 Oct;
5:14733.
PMID: 26435193
Ubiquitin modification of the TGF-β pathway components is emerging as a key mechanism of TGF-β pathway regulation. To limit TGF-β responses, TGF-β signaling is regulated through a negative feedback loop...